Please login to the form below

Not currently logged in

Rare Diseases and Orphan Drugs

Sponsored by

Back to Results


75 Not Out

By: Celgene UK

Summary of work

MDS is a group of haematological malignancies that occur when blood cells remain in an immature or ‘blast’ stage within the bone marrow and never develop into mature cells capable of performing their necessary functions.

The average age of diagnosis for an MDS patient is 73. Patients with higher-risk MDS have a median survival of approximately six to 12 months. They must often rely on blood transfusions to manage symptoms of anaemia and extreme fatigue, which may result in life-threatening toxicity.

In this elderly population with limited alternative treatment options VIDAZA® trebles the two-year overall survival of patients over 75 years old. However market research suggested that this benefit was not being realised in practice, as the majority of VIDAZA® use was in the 65-75 year old population.

Further market research indicated that clinicians were concerned about treating elderly patients with co-morbidities and the challenges of keeping older patients on therapy.

Celgene developed a ‘75 not out!’ campaign focused on patients 75 and over. As a result of the change in focus, market share increased substantially in this patient group and most importantly hundreds of elderly MDS patients trebled their chances of surviving past the two-year mark.

Judges' comments

75 Not Out had a powerful communications message that tackled ageism head on, engaging stakeholders well and demonstrating a strong focus on a particular patient segment. It’s an important initiative to help change perceptions about treating the elderly.


75 Not Out - By: Celgene UK

The Inside Story - Pompe and Fabry Disease - By: Sanofi Genzyme
With support from: Havas Life Medicom

Disease Awareness Animated Infographic - By: Shire
With support from: TVF Communications

“Let’s talk tyrosinaemia” - By: Sobi (Swedish Orphan Biovitrum AB)
With support from: Atlantis Healthcare

Key dates

Entry deadline 25 August 2023
Extended entry deadline 1 September 2023*
*additional fee applies
Judging Day 10 October 2023
Company/Team of the Year Interviews 3 November 2023
PMEA Event 22 November 2023